I am a board-certified medical oncologist who specializes in caring for people with plasma cell cancers. These include multiple myeloma, asymptomatic (smoldering) multiple myeloma, and monoclonal gammopathy of undetermined significance (MGUS).
Read more Read less
As a doctor, my goal is to guide patients as we consider options for their care including the full array of clinical trials offered at MSK. My philosophy is to consider not only the details of my patients’ disease but also their priorities and quality of life, so that I can provide the right treatments for them.
My research is aimed at bringing chimeric antigen receptor (CAR) T cell therapy to people with multiple myeloma. My goal is to move the field of CAR T cell therapy forward so that we can provide the safest, most effective cellular therapy options for our patients. A clinical trial based on my laboratory research for patients with relapsed myeloma was opened in March 2017 and is currently enrolling.
- Clinical Expertise: Multiple Myeloma; Smoldering Myeloma; Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Languages Spoken: English
- Education: MD, Mount Sinai School of Medicine
- Residencies: Internal Medicine - Mount Sinai Hospital
- Fellowships: Medical Oncology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Medical Oncology; Internal Medicine
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Read more Read less
Clinical Trials Led by Eric Smith
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more